6 48

Cited 0 times in

병발한 진행성 간세포암과 신장암을 절제 후 반복적인 경간동맥화학색전술 및 Sorafenib으로 관해 유도한 1예

DC Field Value Language
dc.contributor.author최진섭-
dc.contributor.author김승업-
dc.contributor.author박준용-
dc.contributor.author이광훈-
dc.contributor.author최영득-
dc.contributor.author조남훈-
dc.contributor.author박영년-
dc.contributor.author안상훈-
dc.contributor.author한광협-
dc.contributor.author전재윤-
dc.contributor.author김도영-
dc.date.accessioned2025-08-14T05:02:04Z-
dc.date.available2025-08-14T05:02:04Z-
dc.date.issued2012-02-
dc.identifier.issn2288-8128-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/207021-
dc.description.abstractAdvanced hepatocellular carcinoma (HCC) is difficult to treat and the survival is poor. Here, we present a patient diagnosed as advanced HCC (stage IIIa) which was supervening with early renal cell cancer (stage I). The patient was treated with pre-operational transarterial chemoembolization (TACE) and surgical resection (right hepatectomy, right nephrectomy, and cholecystectomy). Sorafenib were taken continually after surgery. Multiple recurred HCC nodules in remnant liver were detected 2 months later after surgery. Combined treatment modalities including 4 sessions of TACE, and 12 cycles of 5-flurouracil (FU)/carboplatin based hepatic arterial infusional chemotherapy (HAIC) induced complete response. After the diagnosis of advanced HCC, the patient survived 36 months and experienced disease-free status for 19 months.-
dc.description.statementOfResponsibilityopen-
dc.languageKorean-
dc.publisher대한간암학회-
dc.relation.isPartOfJournal of Liver Cancer(대한간암학회지)-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.title병발한 진행성 간세포암과 신장암을 절제 후 반복적인 경간동맥화학색전술 및 Sorafenib으로 관해 유도한 1예-
dc.title.alternativeA Case of Advanced Hepatocellular Carcinoma which was Supervening with Renal Cell Cancer Cured by Repeated Transarterial Chemoembolization and Sorafenib after Resection-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Surgery (외과학교실)-
dc.contributor.googleauthor김번-
dc.contributor.googleauthor민재훈-
dc.contributor.googleauthor김승업-
dc.contributor.googleauthor박준용-
dc.contributor.googleauthor이광훈-
dc.contributor.googleauthor이도연-
dc.contributor.googleauthor최진섭-
dc.contributor.googleauthor최영득-
dc.contributor.googleauthor조남훈-
dc.contributor.googleauthor박영년-
dc.contributor.googleauthor안상훈-
dc.contributor.googleauthor한광협-
dc.contributor.googleauthor전재윤-
dc.contributor.googleauthor김도영-
dc.contributor.localIdA04199-
dc.contributor.localIdA00654-
dc.contributor.localIdA01675-
dc.contributor.localIdA02675-
dc.contributor.localIdA04111-
dc.contributor.localIdA03812-
dc.contributor.localIdA01563-
dc.contributor.localIdA02226-
dc.contributor.localIdA04268-
dc.contributor.localIdA03544-
dc.contributor.localIdA00385-
dc.relation.journalcodeJ03078-
dc.identifier.eissn2383-5001-
dc.subject.keywordHepatocellular carcinoma-
dc.subject.keywordRenal cell carcinoma-
dc.subject.keywordSorafenib-
dc.subject.keywordTransarterial chemoembolization-
dc.subject.keywordHepatic artery infusional chemotherapy-
dc.subject.keywordResection-
dc.contributor.alternativeNameChoi, Jin Sub-
dc.contributor.affiliatedAuthor최진섭-
dc.contributor.affiliatedAuthor김승업-
dc.contributor.affiliatedAuthor박준용-
dc.contributor.affiliatedAuthor이광훈-
dc.contributor.affiliatedAuthor최영득-
dc.contributor.affiliatedAuthor조남훈-
dc.contributor.affiliatedAuthor박영년-
dc.contributor.affiliatedAuthor안상훈-
dc.contributor.affiliatedAuthor한광협-
dc.contributor.affiliatedAuthor전재윤-
dc.contributor.affiliatedAuthor김도영-
dc.citation.volume12-
dc.citation.number1-
dc.citation.startPage51-
dc.citation.endPage57-
dc.identifier.bibliographicCitationJournal of Liver Cancer (대한간암학회지), Vol.12(1) : 51-57, 2012-02-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Surgery (외과학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Urology (비뇨의학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Pathology (병리학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.